Matuschek Christiane, Bölke Edwin, Haussmann Jan, Mohrmann Svjetlana, Nestle-Krämling Carolin, Gerber Peter Arne, Corradini Stefanie, Orth Klaus, Kammers Kai, Budach Wilfried
Department of Radiation Oncology, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany.
Klinik für Strahlentherapie und Radiologische Onkologie, Heinrich Heine Universität, Moorenstr. 5, D-40225, Düsseldorf, Germany.
Radiat Oncol. 2017 Mar 23;12(1):60. doi: 10.1186/s13014-017-0796-x.
PURPOSE/OBJECTIVE(S): It is currently unclear whether patients with low risk breast cancer receiving adjuvant endocrine therapy need adjuvant radiation therapy after breast conserving surgery. The data of randomized trials are available.
MATERIALS/METHODS: In a database search 5 randomized trials including in total 3766 mostly elderly patients with early stage breast cancer treated either with adjuvant endocrine therapy or with endocrine therapy and additional whole breast radiation after breast conserving surgery were identified. Published hazard ratios for time to local recurrence were the basis of our meta-analysis. Meta-analysis of the effect sizes on local recurrence was performed using a random effects model based on parameter estimates of log hazard ratios in Cox models and their standard errors. Furthermore, overall survival was examined.
Adjuvant hormone therapy alone in mostly older patients with low risk breast cancer resulted in significantly shorter time to local relapse compared to radiation therapy combined with hormone therapy (Hazard Ratio: 6.8, 95% CI: 4.23-10.93, p < 0.0001) . There was no significant difference for overall survival.
Additional radiation therapy to hormone therapy did improve local relapse in breast cancer patients but did not show significant impact on overall survival.
目前尚不清楚接受辅助内分泌治疗的低风险乳腺癌患者在保乳手术后是否需要辅助放疗。现有随机试验的数据。
通过数据库检索,确定了5项随机试验,共纳入3766例大多为老年的早期乳腺癌患者,这些患者接受了辅助内分泌治疗,或在保乳手术后接受了内分泌治疗及额外的全乳放疗。已发表的局部复发时间风险比是我们进行荟萃分析的基础。基于Cox模型中对数风险比的参数估计及其标准误差,使用随机效应模型对局部复发的效应大小进行荟萃分析。此外,还对总生存期进行了研究。
在大多为老年的低风险乳腺癌患者中,单纯辅助激素治疗与放疗联合激素治疗相比,局部复发时间显著缩短(风险比:6.8,95%置信区间:4.23 - 10.93,p < 0.0001)。总生存期无显著差异。
激素治疗联合额外放疗确实改善了乳腺癌患者的局部复发,但对总生存期无显著影响。